AJP Asia Intelligence Agency

Samsung Biologics Attracts 11.4 Trillion Won in Capital Increase for PolyPeptide Acquisition


Samsung Biologics reported that over 11 trillion won was raised in its recent capital increase offering. The funds will be used to finalize the acquisition of global peptide contract development and manufacturing organization (CDMO) PolyPeptide Group.
 
The company announced on November 16 that 9,745,071 shares were subscribed during the public offering held from November 12 to 13, achieving a subscription rate of 135.6 to 1. The total subscription amount reached 11.4407 trillion won, marking the largest scale in history for a public offering following a rights offering. Considering the new share issuance price of 1,174,000 won, investors needed to contribute approximately 160 million won to receive one share.
 
This public offering targeted the remaining 71,854 shares after subscriptions from existing shareholders and employee stock ownership plans. In the previous rights offering held on November 9 and 10, 96.8% of the total 2.27 million shares issued were subscribed, with 2,198,146 shares taken up. Samsung Biologics plans to issue 2.27 million common shares at 1,174,000 won each, raising a total of 2.665 trillion won.

The raised funds will be allocated for the acquisition of PolyPeptide Group. Samsung Biologics signed an acquisition agreement with PolyPeptide Group in July, with the purchase price set at 1.46 billion Swiss francs (approximately 2.7 trillion won at the time of announcement), making it the largest merger and acquisition deal in the domestic pharmaceutical and biotech industry. The recent tender offer saw a response rate of 97.98% for the shares, and the company plans to secure 100% ownership through compulsory acquisition.
 
With this acquisition, Samsung Biologics aims to expand its CDMO business into the peptide sector, following its existing capabilities in antibody drugs, messenger RNA (mRNA), and antibody-drug conjugates (ADC).
 
The peptide market is rapidly growing as obesity and diabetes treatments increasingly rely on peptide-based development and production. The global peptide pharmaceuticals market, valued at $94 billion last year, is projected to grow at an average annual rate of 13.4%, reaching $200 billion by 2031.
 
This capital increase was conducted through a public offering of unsubscribed shares after the rights offering. The process will conclude with the payment of the subscription amount on the 17th and the listing of new shares on the 30th.




* This article has been translated by AI.